| 6.28 Delayed Data As of Jun 14 |  -0.47 / -6.96%Today’s Change | 4.82 Today|||52-Week Range 15.00 | -20.20% Year-to-Date |
| CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Jun 12 / Zacks.comZAK - Paid Partner Content | CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of S... Jun 11 / GlobeNewswirePNW - Paid Partner Content |
| Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Jun 12 / Zacks.comZAK - Paid Partner Content | Steven Cohen Takes an Interest in CymaBay Therapeutics Jun 10 / GuruFocus NewsGURU - Paid Partner Content |
| Why Beyond Meat, Lovesac, and CymaBay Therapeutics Slumped Today Jun 11 / MotleyFool.comFOO - Paid Partner Content | CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DD... May 20 / GlobeNewswirePNW - Paid Partner Content |
| Here's Why CymaBay Therapeutics Collapsed Today Jun 11 / MotleyFool.comFOO - Paid Partner Content |
| Previous close | 6.75 |
| Today’s open | 6.69 |
| Day’s range | 6.24 - 6.80 |
| Volume | 1,425,267 |
| Average volume (3 months) | 1,106,983 |
| Market cap | $431.4M |
| Earnings growth (last year) | -58.86% |
| Earnings growth (this year) | -16.10% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 2.19 |
| Today’s change | Today’s % change | |
|---|---|---|
| DITAMCON Distributing C... | +2.29 | +2.51% |
| APLSApellis Pharmaceutic... | -0.22 | -1.03% |
| NUSNU Skin Enterprises ... | -0.35 | -0.68% |
| HLFHerbalife Nutrition ... | +0.64 | +1.47% |
| Next reporting date | August 5, 2019 |
| EPS forecast (this quarter) | -$0.36 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$72.5M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Sujal Shah |
Chief Scientific Officer & Senior Vice President Charles A. McWherter |
Corporate headquarters Newark, California |
